Connecting you to market-leading technologies
Home » My Dream CLD Lab – Part 4: PAIA product titer and glycosylation screening assays

< News page

MY DREAM CLD LAB

Part 4: PAIA product titer and glycosylation screening assays

For the next addition to my Dream CLD Laboratory, I’m looking at the analytical side of my workflow. One thing scientists are always hoping to do is shorten their time to market – and a great way to do this is to find an early indication of which of their clones may be the highest producing and best quality, prior to later expansion steps. 

PAIA Biotech have taken on this challenge by developing simple to use, plate-based assays to get an idea of the productivity and quality of clones earlier in the CLD process. This is accomplished by PAIA’s antibody quantification kit or the glycan screening kit.

Each of these kits use the same principal technology – 384 well plates come pre-loaded with specific capture beads, and reagents are included for detection of the analyte within the sample. The sample and reagent are added to the wells and following sedimentation the fluorescence intensity is measured from the bottom of the well. What makes PAIA’s technology unique is that rather than measuring the amount of bead-bound fluorescence (which requires extra separation and washing steps), the PAIAplate allows for measurements to be made directly from the unbound reagent. The fluorescence detected is inversely proportional to the fluorescence bound by the beads, allowing for quantitative measurements of analyte present in the samples.

The PAIA plate-based product titer and glycan screening assays are an easy solution to save time in your workflow for the following reasons:

Convenient

PAIA designed these assays specifically to be an ultra-convenient solution for scientists. As described above, the assays come in pre-measured kits and require very low samples volumes (5-10 uL) per well. Also, these samples can be crude supernatants – which means few dispensing steps and no sample prep.

Automation ready

With automation quickly becoming a part of every CLD workflow, the PAIA assays are automation ready for liquid handling platforms. Fast measurements can be accomplished on standard fluorescence plate readers. Did you know – PAIA plates can be read on SYNENTEC’s NyONE and Cellavista automated imagers? (That’s a bonus for me as I’ve already added a NyONE to my dream CLD lab!)

No purification required

Unlike similar processes and products on the market, both PAIA’s product titer and glycan assays can be performed without purification. This is a major benefit of the glycan assay in particular, as purification steps add a significant amount of time and effort. Another benefit to highlight – PAIA’s glycan kit is the only screening technique capable of measuring core fucosylation or terminal galactosylation.

PAIA’s platform technology has applications across the board, from monoclonal antibody production to cell & gene therapy and production of ATMPs, as well as bioprocessing. For a convenient method of determining the highest producing and best quality clones early in my workflow and ultimately saving me precious time, PAIA plate-based assays certainly have a place on my wishlist for my Dream CLD Laboratory.

To discuss any of my recommendations please get in contact with me at eharrington@bioprocess-eng.co.uk – I would love to discuss your process with you.

ELLEN_Square

Article by:
Ellen Harrington
Technical Sales Specialist
E. eharrington@bioprocess-eng.co.uk

 

Find out more about PAIA >

Other PAIA news